U.S. Entertainment Stock News

A federal judge has allowed key investor fraud claims against Scotts Miracle-Gro (NYSE:SMG) to proceed, focusing on alleged misstatements around demand, inventory, and the Hawthorne cannabis unit. The ruling keeps senior management and the company under legal scrutiny, extending an ongoing securities lawsuit rather than dismissing it outright. This development adds a layer of litigation and governance risk that sits alongside existing discussions of earnings, debt, and recovery efforts. For...

Recent leadership changes at Fortune Brands Innovations (FBIN), including interim management following activist investor pressure and a canceled CEO appointment, have put the stock in focus ahead of the Q1 2026 earnings report. See our latest analysis for Fortune Brands Innovations. The leadership turmoil and fresh dividend declaration are playing out against a share price that has fallen around 33% over 90 days and a 1 year total shareholder return of about 15% in decline. Shorter term price...

Axcelis Technologies (ACLS) is approaching a closely watched catalyst, with Q1 2026 results and an earnings call scheduled for May 7. Analysts are focusing on profitability pressures and softer revenue expectations. See our latest analysis for Axcelis Technologies. The stock has been on a sharp upswing, with a 1 month share price return of 75.38% and year to date share price return of 98.56%, while the 1 year total shareholder return is 194.42%. This indicates strong momentum into the Q1 2026...

Lumen Technologies (LUMN) opened Q1 2026 with revenue of US$2.9 billion and a basic EPS loss of US$0.20, alongside net income excluding extra items of a US$200 million loss. Over recent quarters, revenue moved from US$3.3 billion in Q4 2024 to US$3.2 billion in Q1 2025 and US$3.0 billion in Q4 2025. Basic EPS shifted from a profit of US$0.09 in Q4 2024 to losses of US$0.20 in Q1 2025 and US$0.00 in Q4 2025. Taken together, these figures frame Q1 2026 as another period where investors are...

Why Crocs stock is back in focus after mixed earnings and guidance Crocs (CROX) just reported first quarter 2026 results showing lower sales and net income year over year, while at the same time tightening second quarter guidance and raising its full year earnings outlook. The combination of softer recent performance and a more confident full year earnings range is giving investors fresh information on how the company sees demand, profitability and its broader footwear portfolio for the rest...

Sarepta Therapeutics (SRPT) stock is reacting to first quarter earnings, where revenue of US$730.8 million compared with US$744.86 million a year earlier, while net income reached US$330.96 million after a prior net loss. See our latest analysis for Sarepta Therapeutics. The latest earnings reversal has arrived after a volatile stretch, with a 90 day share price return of 35.23% and a 1 year total shareholder return decline of 37.28%, suggesting that recent momentum contrasts with longer term...

In the first quarter of 2026, Universal Health Services reported higher revenue of US$4,495.18 million and net income of US$348.68 million, while also repurchasing 675,000 shares for US$127.3 million and arranging up to US$900 million in new credit facilities partly to fund its Talkspace acquisition. This combination of stronger profitability, continued share repurchases, and additional financing capacity suggests management is actively reshaping the company’s capital structure and...

KLA (NasdaqGS:KLAC) announced a ten-for-one stock split alongside a 21% increase in its dividend. The company is also positioned to supply inspection and process control equipment to the planned Terafab U.S. chip fabrication project focused on advanced AI processors. These developments are new for KLA and are expected to influence how investors think about the stock and its role in future U.S. chip production. For context, KLA shares recently closed at $1,816.29, with the stock up 17.9%...

Adaptive Biotechnologies (ADPT) opened Q1 2026 with revenue of US$70.9 million and a basic EPS loss of US$0.13, alongside a net loss of US$20.0 million. Over recent quarters the company has seen revenue move from US$47.5 million in Q4 2024 to US$52.4 million in Q1 2025, US$58.9 million in Q2 2025, US$94.0 million in Q3 2025 and US$71.7 million in Q4 2025. Quarterly EPS ranged from a loss of US$0.23 in Q4 2024 to a profit of US$0.06 in Q3 2025 and back to a loss of US$0.09 in Q4 2025, putting...

Genius Sports Limited has reported first-quarter 2026 results, with sales rising to US$187.95 million from US$143.99 million a year earlier, while net loss widened to US$55.47 million and loss per share increased to US$0.21. Alongside these results, Genius Sports has rolled out its GeniusIQ data and AI platform across every Liga MX stadium, positioning its technology at the center of Mexican soccer’s officiating, fan engagement, and sponsorship infrastructure. Next, we’ll explore how Genius...

The RMR Group Inc. has reported past second-quarter 2026 results, with sales rising to US$5.1 million while revenue fell to US$145.63 million, and quarterly net income declining to US$1.01 million, or US$0.05 per diluted share, compared with the prior year period. Over the first six months of fiscal 2026, higher sales but lower revenue coincided with net income improving to US$13.2 million, highlighting a contrast between weaker quarterly profitability and stronger year‑to‑date earnings. We...

Crown Holdings’ recent first-quarter 2026 results showed sales rising to US$3,259 million while net income and earnings per share eased, and the company affirmed a quarterly dividend of US$0.35 per share payable on May 28, 2026. At the same time, Crown announced plans for a new beverage can plant in Northern India capable of producing about 2.20 billion cans annually, supported by long-term customer commitments that underline demand for aluminum packaging. With higher volumes but pressured...

United Airlines Holdings (UAL) stock is back in focus after Q1 2026 results came in ahead of expectations, with management leaning on tighter capacity and pricing to help offset fuel volatility and support margins. See our latest analysis for United Airlines Holdings. The recent 6.8% 1 day and 12.0% 30 day share price returns suggest momentum is rebuilding after a weaker period. The 1 year total shareholder return of 26.0% and 3 year total shareholder return of about 12x indicate longer term...

Stock performance and recent context W. R. Berkley (WRB) has seen mixed share performance recently, with the stock near US$66 and returns showing modest movement over the past week and month, but a more pronounced decline over the past 3 months and year. See our latest analysis for W. R. Berkley. Recent trading has been soft, with a 90 day share price return of about a 7% decline and a 1 year total shareholder return of about a 7% decline, even though the 3 and 5 year total shareholder...

Wondering if Robinhood Markets at around US$79 per share is still compelling value or if the easy gains are behind it? This article breaks down what the current price really reflects. The stock has been volatile recently, with an 11% return over the last 7 days, 13.3% over the last 30 days, a 31.4% decline year to date, and a 58.1% return over the last year, which can shift how the market is thinking about both opportunity and risk. Recent coverage has focused on Robinhood's evolving role in...

What recent moves in Veradermics (MANE) might be telling you Veradermics (MANE) has drawn attention after a sharp month return of about 72% and a very large past 3 months move, putting its clinical stage dermatology pipeline and valuation in sharper focus for investors. See our latest analysis for Veradermics. The recent 72% 30 day share price return and very large 90 day move sit alongside a 190.78% year to date share price return, which points to strong upward momentum despite a 4.38% one...

Investors may be wondering whether United Therapeutics at around US$596.76 is still offering value after a strong run, or if the easy gains are already behind it. The stock has recent returns of 4.5% over 7 days, 6.6% over 30 days, 20.1% year to date, 94.4% over 1 year and 181.2% over 3 years. This puts valuation questions front and center for anyone considering it today. Recent coverage has focused on United Therapeutics as a high growth biotech with a strong pipeline and regulatory...

Pool Corporation (NasdaqGS:POOL) has announced the immediate departure of CEO Peter D. Arvan. John B. Watwood has been appointed as the new President and CEO, with John E. Stokely becoming Executive Chair. The company has postponed its upcoming Investor Day following the leadership change. Pool enters this leadership transition after a period of weak share price performance, with NasdaqGS:POOL at $188.09 and showing a 10.3% decline over the past week and 35.2% decline over the past year...

Gold Royalty Corp. has reported its first-quarter 2026 results, with sales rising to US$7.18 million and net income reaching US$1.77 million. The shift from a net loss a year earlier to positive earnings per share, alongside ample cash and no debt, highlights a marked improvement in financial flexibility. We'll examine how Gold Royalty's return to profitability and reaffirmed 2026 production outlook may influence its longer-term investment narrative. The future of work is here. Discover the...

DICK'S Sporting Goods (DKS) is in focus after recent share price moves, with the stock last closing at $226.50. Investors are weighing this performance against the company’s broader returns and current business profile. See our latest analysis for DICK'S Sporting Goods. The latest 5.11% 1 day share price return adds to a 13.44% 30 day share price return and a 23.16% 1 year total shareholder return. This suggests momentum has been building rather than fading recently. If DICK'S Sporting Goods...

Centrus Energy (LEU) opened Q1 2026 with revenue of US$76.7 million and basic EPS of US$0.51, against a backdrop of forecast earnings growth of about 7.0% a year and revenue growth around 5.1%. Over recent quarters the company has seen revenue range between US$73.1 million and US$154.5 million with basic EPS between US$0.21 and US$3.21. Trailing 12 month EPS sits at US$3.25 on revenue of US$452.3 million and net income of US$60.6 million, framing a set of results where profit growth and...

In late April 2026, Glaukos Corporation reported first‑quarter 2026 sales of US$150.57 million, a rise from US$106.66 million a year earlier, alongside a net loss of US$19.78 million, and raised its 2026 net sales guidance to a range of US$620 million to US$635 million. At the same time, Glaukos highlighted a broadened ophthalmic portfolio and long-term growth plan, even as insider share sales and continued losses underline ongoing execution and commercialization risks. We’ll now explore how...

Insmed (NasdaqGS:INSM) has launched a national "Suspect Bronchiectasis" awareness initiative with TV personality and patient advocate Ty Pennington. The company is partnering with the American Thoracic Society on a quality improvement effort aimed at reducing underdiagnosis of bronchiectasis among clinicians. The campaign targets both physicians and undiagnosed patients, with potential implications for uptake of Insmed therapies such as Brinsupri and ARIKAYCE. For investors tracking Insmed,...

Wondering if MKS at around US$293.77 is still offering value after a strong run, or if you might be turning up late to the story. The stock has posted returns of 10.7% over 7 days, 24.0% over 30 days, 74.5% year to date, 298.2% over 1 year and 255.7% over 3 years, with a 5 year return of 83.9%. These moves have kept MKS firmly on investors' radars, as sustained share price strength often raises questions about how the current price lines up with underlying fundamentals. With this context in...